AD

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Plasma, AD, Simoa, Food, Biomarker, CSF, Neurology, Pathology, Psychiatry, Threonine, Deficit spending, Lucent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, PET, Cerebrospinal fluid, CLIA, University of Pittsburgh School of Medicine, Diagnosis, Antibody, Alzheimer's disease, Blood, DSM-IV codes, University, Wilfrid Sellars, Patient, Associate, Medical imaging, Medical device

Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217.

Key Points: 
  • Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217.
  • p-Tau 217 has emerged as a top performing biomarker for Alzheimer’s pathology, enabling clinical sensitivity and specificity in blood.
  • Highly sensitive and specific blood-based biomarker tests have the potential to speed diagnosis and expand access to treatments for millions of individuals with early Alzheimer’s disease.
  • LucentAD p-Tau 217 leverages the combination of Quanterix’s ultra-sensitive Simoa® technology and J&J Innovative Medicine’s extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow.

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, FDA, AD, PD, NYSE, Bio, III, II, Human, Axonal transport, Neuroprotection, Mutation, Inflammation, Research, Protein, Clinical trial, Mouse, Parkinson's disease, Animal, New Drug Application, Brain, Buntanetap, NDA, Movement, Interim analysis, Neurotoxicity, Cognition, Pharmaceutical industry, Vaccine, Dietary supplement, Alzheimer's disease, Disease

Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.
  • This novel mechanism of action makes Annovis' drug a potentially effective treatment option for AD and also for PD.
  • The posters' collective findings highlight a highly promising treatment for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.
  • Cheng Fang , Ph.D., senior vice president of research and development at Annovis Bio, is presenting two posters at CTAD.

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
AD, Life, Behavior, Pathology, Amnesia, Doctor of Philosophy, CNS, Deficit spending, Health, Clinical trial, Personality, Poster, Dementia, Memory, Confusion, University, Language, Patient, Communication, Cognition, Medical device, Medical imaging, Alzheimer's disease, Disease, Cumulus cloud

Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.

Key Points: 
  • Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.
  • BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting on Wednesday October 25th in Boston, Massachusetts.
  • Cumulus presented three poster presentations, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a study sponsored by INmune Bio Inc. (Nasdaq: INMB) a clinical stage biopharma company.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, FDA, Fruit, AD, Ageing, NYSE, Biomarker, CSF, Physician, Apolipoprotein E, Neurology, Data, Conference, AB, Health, Dementia, Protein, PET, Cerebrospinal fluid, DGX, Risk, Marketing, Quest Diagnostics, Test, Diagnosis, Patient, IP, Pharmaceutical industry, Medical imaging, Quest, Alzheimer's disease, Diadem

MILAN and SECAUCUS, N.J., Oct. 25, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of Alzheimer's disease.

Key Points: 
  • Under terms of the agreement, Diadem has licensed exclusive U.S. rights to the intellectual property of its AlzoSure® Predict blood-based prognostic technology to Quest for the purpose of developing, validating and marketing a laboratory-developed test service for providers and patients in the U.S. Financial details of the agreement were not disclosed.
  • "Reliable, convenient and affordable blood tests are essential to the identification of AD risk in early stages, when interventions hold the greatest potential to slow disease progression," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics.
  • Quest Diagnostics has a long-standing history of advancing diagnostic innovation in the field of dementia, including Alzheimer's disease.
  • The company continues to explore the potential of other biomarkers for assessing AD risk that may complement its existing portfolio.

BrainCheck Expands First End-to-End Solution for Cognitive Care

Retrieved on: 
Tuesday, October 24, 2023
Summit Health, Alzheimer's disease, University of Washington School of Medicine, National Alzheimer's Project Act, Moca, Trial of the century, AD, Montreal Cognitive Assessment, Health information management, Medicare, Breast Cancer Awareness Month, Data, Deficit spending, D.O, Health, Research, Clinical trial, Dementia, Severity, Tablet, University, MSE, EHR, Patient, Computerize, Montreal, Cholesterol, Medical imaging, Medical device, MD, Index

AUSTIN, Texas, Oct. 24, 2023 /PRNewswire/ -- BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheck® Screen™, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts from October 24-27, ahead of National Alzheimer's Awareness Month. New research supporting BrainCheck's comprehensive digital cognitive assessment tool will also be presented at the meeting.

Key Points: 
  • "More than six million Americans have Alzheimer's disease (AD), the most common type of dementia, but unfortunately many remain undiagnosed,i" said Kim Rodriguez, CEO of BrainCheck.
  • "Early diagnosis will help close this gap, and our platform empowers providers to easily access information on patients' cognitive health by offering a unique solution that includes screening, assessment, care planning, and monitoring.
  • The latest version brings cognitive care to the next level, expanding access to our technology from any device or location, in-clinic or remote.
  • The next generation of the BrainCheck platform allows digital cognitive testing on any internet-connected device – including phones, tablets and browsers – regardless of the patient or clinician's location.

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Retrieved on: 
Tuesday, October 24, 2023
Alzheimer's disease, CRVO, Attention, Plasma, AD, Three-body problem, Neurology, MD, Publication, CNS, DLB, HIV disease progression rates, Basal forebrain, Ganz railcar (Ferrocarriles Vascongados, short version), Dementia, Nature Communications, American Academy, Drug development, Brain, Lewy body, Patient, Molecular Neurodegeneration, Pharmaceutical industry, Medical imaging

BOSTON, Oct. 24, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD):

Key Points: 
  • Neurology® is the medical journal of the American Academy of Neurology.
  • The journal has released the final publication, including a Short Version in print, of the article that was the subject of a press release from CervoMed dated September 6th, 2023.
  • Alam J and Nixon RA, Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.
  • "As reported in Nature Communications last year, the primary analysis of the phase 2a study of DLB showed neflamapimod significantly improved dementia severity and motor function.

Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China

Retrieved on: 
Tuesday, October 24, 2023
Alzheimer's disease, Amyloid, FDA, LMI, United Kingdom, Trial of the century, AD, Radiopharmaceutical, NMPA, Plaque, MCI, Food, Medication, Physician, European Medicines Agency, Dementia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, PET, Disease, MHRA, National Medical Products Administration, EMA, Brain, Medicines and Healthcare products Regulatory Agency, GMP, Patient, Diagnosis, Medical imaging

BERLIN and BEIJING, Oct. 24, 2023 /PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18 injection) has received regulatory approval from National Medical Products Administration (NMPA) in China. Neuraceq® (欧韦宁®), an amyloid PET imaging radiotracer, is the first radiopharmaceutical targeting β-amyloid approved in China to be used to support diagnosis of Alzheimer's disease (AD). It visualizes beta-amyloid plaque accumulation in the brain, an established biomarker for AD. Neuraceq® (欧韦宁®) will be manufactured by Sinotau and made commercially available. With this diagnostic tool, Chinese physicians will have access to state-of-the-art imaging technology to accurately evaluate patients with cognitive decline. The density of amyloid plaques can be assessed to guide early diagnosis and patient management.

Key Points: 
  • BERLIN and BEIJING, Oct. 24, 2023 /PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18 injection) has received regulatory approval from National Medical Products Administration (NMPA) in China.
  • Neuraceq® (欧韦宁®), an amyloid PET imaging radiotracer, is the first radiopharmaceutical targeting β-amyloid approved in China to be used to support diagnosis of Alzheimer's disease (AD).
  • With this diagnostic tool, Chinese physicians will have access to state-of-the-art imaging technology to accurately evaluate patients with cognitive decline.
  • "Neuraceq® (欧韦宁®), an amyloid PET imaging radiotracer which can be imaged through PET-CT/MRI is the first approved Aβ-PET tracer in China and the first approved PET tracer in China in recent 20 years.

Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Laboratory developed test, AD, Alzheimer's disease, Janssen, Biomarker, CSF, LDT, PET, Accelerator, RUO, Antibody, Neurology, Corporation, Johnson & Johnson, Diagnosis, Pharmaceutical industry, Medical imaging, Disease

Under this agreement, Quanterix will receive worldwide, non-exclusive rights to J&J’s extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix’s position at the forefront of the Alzheimer's Disease (AD) biomarker field.

Key Points: 
  • Under this agreement, Quanterix will receive worldwide, non-exclusive rights to J&J’s extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix’s position at the forefront of the Alzheimer's Disease (AD) biomarker field.
  • Under the terms of the license agreement, Janssen will grant Quanterix a worldwide non-exclusive license for J&J-developed technology to produce Simoa p-Tau 217 research-use only (RUO) assay kits for global distribution.
  • Furthermore, under the agreement Quanterix will launch a Laboratory Developed Test (LDT) based on the J&J p-Tau 217 antibodies and assay, offered through Accelerator under the Lucent Diagnostics brand.
  • "This collaboration demonstrates the scientific advances that are possible when Simoa’s ultra-sensitive detection is combined with clinically validated antibodies and critical reagents,” said Masoud Toloue, CEO of Quanterix.

Veritas™ 360 Defense to Deliver Cyber Resilience On-Prem and Across Clouds

Retrieved on: 
Monday, October 23, 2023
Data Management, Security, Technology, Software, Networks, Internet, AD, Ecosystem, Veritas Technologies, Rio (hotel and casino), Active Directory, Architecture, Face, PwC, Organization, Dreamscape, Data management, CrowdStrike, Information technology, Environment, Validation, Falcon, Risk, Confusion, API, Defense, Video game, Risk management, Cryptocurrency, Online shopping, Qualys, Kubernetes, Veritas, CyberArk, Broadcom Inc., Symantec

Veritas Technologies , the leader in secure multi-cloud data resilience, today announced Veritas 360 Defense, the first extensible architecture in its space that brings together leading data protection, data governance, and data security capabilities.

Key Points: 
  • Veritas Technologies , the leader in secure multi-cloud data resilience, today announced Veritas 360 Defense, the first extensible architecture in its space that brings together leading data protection, data governance, and data security capabilities.
  • Veritas 360 Defense delivers a unique set of cyber resilience capabilities integrated with leading security vendors, such as CrowdStrike , CyberArk , Qualys , Semperis and Symantec by Broadcom .
  • Veritas 360 Defense has been battle tested against real-world ransomware variants in the Veritas REDLab.
  • Integrated with Veritas™ 360 Defense, Qualys Vulnerability Management, Detection and Response (VMDR) with Integrated Patch Management capabilities delivers the best cyber resilience on-prem and across the cloud."

Semperis and Veritas to Protect Enterprises from Cyberattacks on Active Directory Systems

Retrieved on: 
Monday, October 23, 2023
Networks, Security, Data Management, Technology, Software, Active Directory, AD, Information privacy, Veritas Technologies, White House, SVP, Microsoft, Organization, Petya and NotPetya, Environment, Ecosystem, Defense, GM, Cryptocurrency, Risk management, Veritas, Maersk, Hydrophis semperi

Semperis , a pioneer in identity-driven cyber resilience, today announced a global relationship with Veritas Technologies , a leader in secure multi-cloud data management, to protect enterprises’ most critical assets and identity systems from cyberattacks.

Key Points: 
  • Semperis , a pioneer in identity-driven cyber resilience, today announced a global relationship with Veritas Technologies , a leader in secure multi-cloud data management, to protect enterprises’ most critical assets and identity systems from cyberattacks.
  • The powerful combination of Semperis Active Directory Forest Recovery (ADFR) and Veritas NetBackup provides enterprises with a comprehensive solution to guard against, and recover from, cyberattacks on Microsoft Active Directory (AD) systems.
  • Disruptions to AD services lead to significant downtime and organizational losses, making AD protection a top security priority.
  • Semperis and Veritas protect the world’s largest companies.